IGM Biosciences, Inc. (IGMS)
NASDAQ: IGMS · Real-Time Price · USD
1.270
+0.010 (0.79%)
Jun 5, 2025, 11:59 AM - Market open

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2023 FY 2022
Period Ending
Dec '23 Dec '22
Engineered Immunoglobulin M Antibodies
2.13M
Log In
Engineered Immunoglobulin M Antibodies Growth
99.25%
Log In

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2023 FY 2022
Period Ending
Dec '23 Dec '22
United States
2.13M
Log In
United States Growth
99.25%
Log In